Click here to view the original post by Healio Ophthalmology.
In addition to our own original articles, the Retina Consultant team expertly curates relevant news and research from leading publications.to provide our readers with a comprehensive view of the retina & ophthalmology landscape, Full credit belongs to the original authors and publication.
By clicking the link above, you will be leaving our site to view an article from its original source.
Sharpen your perspective. Get our weekly analysis of the news shaping the retina industry.
Editor’s note: This is a developing news story. Please check back soon for updates.
The FDA approved the Tecnis PureSee IOL, an extended depth of focus IOL for cataract surgery, according to a press release from Johnson & Johnson.
A previous analysis of the lens found that 97% of patients reported “no very bothersome visual disturbances,” with 97% of patients reporting that they would recommend the IOL to friends and family.
According to the release, this is the first FDAapproved extended depth of focus IOL with no warning on loss of contrast sensitivity. In addition, it reduces the impact